Colin Buss assists the firm in biotechnology patent prosecution. He has extensive knowledge in the areas of immune cell profiling, nanoparticle characterization, primary cell isolation, RNAi, gene cloning, immunochemistry and animal models of infectious disease and cancer.
Prior to joining Wolf Greenfield, Colin was a graduate research assistant at MIT. His research focused on diagnostic nanotechnology and immunotherapy nanotechnology. He concentrated on adapting nanoparticle technologies for the diagnosis, treatment and monitoring of disease, with applications in Gram-negative bacterial pneumonia, breast cancer, colon cancer and melanoma, including extensive work in immunotherapy.
Colin received his PhD in Medical Engineering and Medical Physics from the Harvard-MIT Health Sciences and Technology program. He is also co-author of a patent.